Product
plasma-derived FVIII/VWF concentrate
1 clinical trial
1 indication
Indication
von Willebrand diseaseClinical trial
Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Subjects With Severe Von Willebrand DiseaseStatus: Recruiting, Estimated PCD: 2024-04-01